FBRX - Forte Biosciences Inc. Debt to Book Capitalization Ratio

The development of skin medications is independent of economic cycles and seasons, while business resilience relies on existing cash reserves. Drug delivery requires strict adherence to pharmaceutical packaging standards to preserve the properties of the agents. The price action of Forte Biosciences, Inc. (FBRX) on the GURU.Markets platform is 0.00, as the company implements automated antibody screening to accelerate the creation of new therapies.

FBRX (Forte Biosciences Inc) Debt to Book Value history from 07/04/2022 to 09/06/2026

Forte Biosciences Inc. (FBRX) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Forte Biosciences, Inc.|FBRX - Analyst Consensus Forecast

- market capitalization data:

Market Value Forte Biosciences Inc|FBRX - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Forte Biosciences|FBRX - Company Net Assets|Market Capitalization to Book Value Ratio fortebiorx.com|FBRX - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Forte Biosciences, Inc.|FBRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Forte Biosciences, Inc|FBRX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Forte Biosciences Inc|FBRX - Company Long-Term Debts|Company Short-Term Debts Forte Biosciences

Summary company analytics:Forte Biosciences, Inc. FBRX

Core merchandise of Forte Biosciences, Inc

This ratio reflects the proportion of borrowed funds within the equity structure, allowing for an assessment of financial stability and the business's degree of dependence on creditors. By analyzing the total debt-to-book capitalization chart, an investor can determine whether Forte Biosciences, Inc. (FBRX) possesses sufficient resources to fund the development of the non-hormonal drug FB-102 without risking an excessive debt load.

Competitors of Forte Biosciences, Inc.